India rejects Novartis cancer drug patent

Marketplace Contributor Apr 1, 2013
HTML EMBED:
COPY

India rejects Novartis cancer drug patent

Marketplace Contributor Apr 1, 2013
HTML EMBED:
COPY

The Supreme Court in India has rejected an attempt by the Swiss drug maker Novartis to patent an update to a cancer treatment called Gleevec — spelled Glivec in some markets. The decision is expected to have a big impact on pharmaceutical companies and health organizations far outside the borders of India.

The BBC’s Rahul Tandon joins Marketplace Morning Report host Jeremy Hobson to discuss the global pharmaceutical market and the new patent ruling.

We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.